关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
' F: k; z. B/ a. r3 q/ Z
作者：来自澳大利亚
5 S$ y- r5 G2 k$ }4 u2 C" c来源：Haematologica. 2011.8.9.
Dear Group,

, d  j) c! K- g2 b: qSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
therapies. Here is a report from Australia on 3 patients who went off Sprycel
2 W% s6 _1 Z. o& b! Hafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.
8 h& L. W7 Y9 G' K
" w( B1 j( E0 ^- l" U' k5 h. _2 S' qThe remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
different from the stopping Gleevec trial in France which only targets patients
. L' y. y0 |4 K# |9 z+ i( J; Uwho have done well on Gleevec.

/ m' ~. }- ?$ M, }5 `8 X( eHopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.

Best Wishes,
0 d# y* b8 Z! m) b9 o/ L3 ]! EAnjana
; S- y' K7 r/ z/ n& K: v8 l

  [2 C6 N. O$ v' i* I. ~6 h; w: p3 H# }3 B
Haematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
8 p" b1 S4 P: ndasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
Adelaide, Australia;

. i5 o9 K0 ^2 A1 S$ C1 ^Abstract
+ o: X  @4 D3 g8 GPatients with chronic myeloid leukemia, treated with imatinib, who have a
# Q# y' j9 `8 mdurable complete molecular response might remain in CMR after stopping
) d7 k/ z  M% m  |treatment. Previous reports of patients stopping treatment in complete molecular
* O9 Y' ^+ F$ z7 Q: ^: \# U4 Sresponse have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
treatment following imatinib failure. Two of the three patients remain in
% F, N  P- [$ i& X6 K0 Zcomplete molecular response more than 12 months after stopping dasatinib. In
- }! l7 `- e+ D; F# }9 h- d; `these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
+ J0 u) A$ Z" o. }& e: ~( _the emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
/ K  e. a* I8 j" h! y6 w$ }: A" C0 ^3 |characteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
disease features.
! h1 x' Y6 N* n& M

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
) o# x! T- e) I9 [0 k- Y( K0 ~9 r' b    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
8 A2 q' \, l8 f) W# }    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。

. X9 o2 P- o2 E; r2 F0 D* v2 t! p作者：来自法国STIM试验
来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事